

Ismene L. Petrakis · Stephanie O'Malley ·
Bruce Rounsville · James Poling ·
Colette McHugh-Strong · John H. Krystal · VA
Naltrexone Study Collaboration Group

Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia

Published online: 4 June 2004
© Springer-Verlag 2004

Psychopharmacology (2004) 172:291–297

In Fig. 1, page 294, the naltrexone data are missing from the graph. The correct figure appears here.




Fig. 1 Mean weekly heavy drinking days (≥ 5 drinks per episode) at baseline and during the active phase for subjects on naltrexone versus placebo

The online version of the original article can be found at <http://dx.doi.org/10.1007/s00213-003-1658-9>

I. L. Petrakis · S. O'Malley · B. Rounsville · J. Poling ·
C. McHugh-Strong · J. H. Krystal
Department of Psychiatry, Yale University,
New Haven, Conn., USA

I. L. Petrakis (✉)
West Haven Veterans Administration Medical Center #116-A,
950 Campbell Avenue,
West Haven, CT 06516, USA
e-mail: ismene.petrakis@yale.edu
Tel.: +1-203-9325711 ext 2244
Fax: +1-203-9374791